RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents
Open Access
- 6 January 2012
- journal article
- research article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in The Journal of pharmacology and experimental therapeutics
- Vol. 341 (1), 90-103
- https://doi.org/10.1124/jpet.111.187740
Abstract
Genetic mutation and pharmacological inhibition of Bruton's tyrosine kinase (Btk) both have been shown to prevent the development of collagen-induced arthritis (CIA) in mice, providing a rationale for the development of Btk inhibitors for treating rheumatoid arthritis (RA). In the present study, we characterized a novel Btk inhibitor, 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one (RN486), in vitro and in rodent models of immune hypersensitivity and arthritis. We demonstrated that RN486 not only potently and selectively inhibited the Btk enzyme, but also displayed functional activities in human cell-based assays in multiple cell types, blocking Fcε receptor cross-linking-induced degranulation in mast cells (IC50 = 2.9 nM), Fcγ receptor engagement-mediated tumor necrosis factor α production in monocytes (IC50 = 7.0 nM), and B cell antigen receptor-induced expression of an activation marker, CD69, in B cells in whole blood (IC50 = 21.0 nM). RN486 displayed similar functional activities in rodent models, effectively preventing type I and type III hypersensitivity responses. More importantly, RN486 produced robust anti-inflammatory and bone-protective effects in mouse CIA and rat adjuvant-induced arthritis (AIA) models. In the AIA model, RN486 inhibited both joint and systemic inflammation either alone or in combination with methotrexate, reducing both paw swelling and inflammatory markers in the blood. Together, our findings not only demonstrate that Btk plays an essential and conserved role in regulating immunoreceptor-mediated immune responses in both humans and rodents, but also provide evidence and mechanistic insights to support the development of selective Btk inhibitors as small-molecule disease-modifying drugs for RA and potentially other autoimmune diseases.Keywords
This publication has 36 references indexed in Scilit:
- An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid ArthritisThe New England Journal of Medicine, 2010
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProceedings of the National Academy of Sciences of the United States of America, 2010
- Myeloid DAP12-associating lectin (MDL)-1 regulates synovial inflammation and bone erosion associated with autoimmune arthritisThe Journal of Experimental Medicine, 2010
- Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritisArthritis Research & Therapy, 2008
- The Tec Family Tyrosine Kinase Btk Regulates RANKL-induced Osteoclast MaturationOnline Journal of Public Health Informatics, 2008
- Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritisArthritis Research & Therapy, 2008
- Soluble cell adhesion molecules (sICAM‐1, sVCAM‐1, and sE‐selectin) in patients with early rheumatoid arthritisScandinavian Journal of Rheumatology, 2007
- High anti-collagen type-II antibody levels and induction of proinflammatory cytokines by anti-collagen antibody-containing immune complexes in vitro characterise a distinct rheumatoid arthritis phenotype associated with acute inflammation at the time of disease onsetAnnals Of The Rheumatic Diseases, 2006
- Further Characterization of FcγRII and FcγRIII Expression by Cultured Human Mast CellsInternational Archives of Allergy and Immunology, 2001
- X‐Linked Agammaglobulinemia: New Approaches to Old Questions based on the Identification of the Defective GeneImmunological Reviews, 1994